Ainos Secures Largest Order in Company History: $9 Million ASE Agreement for 5,000 Additional AI Nose Systems
The agreement provides for a 50% upfront deposit to support order fulfillment and working capital needs.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ainos (NASDAQ:AIMD) signed a $9 million purchase agreement with ASE Technology Holding for additional AI Nose chemical-sensing systems used in semiconductor manufacturing. The order covers 5,000 additional systems and is the largest single purchase order by value in Ainos' history. It follows completed delivery of 1,400 systems under a previous $2.1 million agreement.
ASE will pay a $4.5 million deposit within 60 days of signing. The remaining 50% is payable through a payment request submitted after delivery with supporting documentation. Revenue will be recognized as contractual performance obligations are satisfied. The expanded deployment will broaden chemical-sensing coverage in ASE manufacturing environments. Separately, Ainos announced in September 2026 that it had begun receiving initial commercial orders in front-end wafer fabrication following technical validation.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point$9 million ASE agreement covers 5,000 additional AI Nose systems, Ainos' largest single order by value. 2.1× market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.$4.5 million deposit is due within 60 days of signing to support fulfillment and working capital.
- Minor point1,400 systems delivered completed the deployment under ASE's previous $2.1 million agreement.
- Minor pointInitial front-end wafer fabrication orders began arriving following technical validation, as announced in September 2026.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Remaining 50% payment requires a payment request after delivery, supported by delivery documentation.
- Minor pointData use remains subject to customer permissions and protection requirements.
- Minor pointNew applications remain subject to validation against their specific requirements.
News Explained
The
Sources and calculations
- Ainos press release (2026-11-12)
- Ainos second-quarter 2026 fundamentals (2026Q2)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,422,912 / ($1,448,333 / 91) = 89.4 days
Details
Market move: AIMD +9.03% vs previous close. AI Nose contract award
On Nov 12, the day this news came out, the latest delayed price for AIMD is 9.03% above the previous close. Argus tracked a peak move of +9.1% during the session. Argus tracked a trough of -11.8% from its starting point during tracking. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $0.53. Relative volume is exceptionally heavy at 109.7x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Purchase agreement
- $9 million
- ASE agreement for additional AI Nose systems
- Additional systems
- 5,000 systems
- Covered by the ASE purchase agreement
- Deposit
- $4.5 million (50%)
- Payable within 60 days of signing
- Remaining payment
- 50%
- Payable after delivery upon a supported payment request
- Prior ASE agreement
- $2.1 million
- Previous agreement under which 1,400 systems were delivered
Previous AI Reports
-
Completed delivery of 1,400 AI Nose systems under ASE’s prior $2.1 million agreement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
performance obligations financial
wafer fabrication technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, TX / ACCESS Newswire / November 12, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has signed a
The purchase builds on the completed delivery of 1,400 systems under the companies' previous
Under the agreement, ASE will pay a
"From field validation and first-phase delivery to ASE's expanded purchase, this record order demonstrates how Chemical Intelligence is progressing from technology development to a business operating at greater scale," said Eddy Tsai, Chairman and Chief Executive Officer of Ainos. "Our customer's larger commitment deepens the relationship and provides a revenue foundation and funding to support our next stage of growth. We are focused on delivering these systems and continuously improving our products so that chemical information can create greater value in process stability, yield improvement and worker safety."
"As advanced packaging technologies evolve, ASE continues to advance smart manufacturing through new sensing capabilities," said ASE. "Together with Ainos, we are expanding chemical sensing coverage to develop a more comprehensive view of conditions across our manufacturing operations. Our joint effort aims to integrate chemical insights with existing manufacturing data to support better-informed decisions on yield and quality, operational efficiency, and personnel safety."
Supporting Yield, Efficiency and Safety in Advanced Packaging
Advanced packaging places stringent demands on process consistency, contamination control and product reliability. As a physical edge node for Chemical Intelligence, AI Nose converts airborne chemical signals into digital information that can be analyzed. It helps engineering teams establish environmental baselines, compare chemical conditions across locations, and track where anomalies emerge and how they evolve-complementing existing process and equipment data.
The expanded deployment will broaden chemical sensing coverage across relevant ASE manufacturing environments, supporting three target objectives:
- Yield and quality: Support contamination management and anomaly investigation, helping teams maintain stable process environments and informing efforts to improve yield and product reliability.
- Efficiency and profitability: Identify environmental changes that may contribute to defects, rework or unplanned downtime, supporting efforts to reduce production losses and improve operational efficiency.
- Worker and facility safety: Support the identification of, and response to, chemical leaks or abnormal releases, helping teams reduce the risk of personnel exposure, equipment damage and operational disruption.
Real-World Data Supports Continuous Improvement and Semiconductor Expansion
Ainos' AI Nose platform has accumulated more than 3 billion real-world chemical data points. These data and field experience provide a foundation for ongoing improvements in system stability, chemical signal analysis and application development. Broader deployment also advances the Company's Chemical Intelligence and Scent AI strategy: physical sensing nodes collect real-world data to support model learning and product improvement, with customer value providing the foundation for wider adoption. Data use will remain subject to customer permissions and protection requirements, and product performance will be validated under application-specific conditions.
In front-end wafer fabrication, Ainos announced in September 2026 that it had begun receiving initial commercial orders following technical validation. The expansion in advanced packaging, together with commercial progress in front-end manufacturing, broadens the Company's semiconductor business foundation. It also provides experience that can support engagement with additional international customers and the development of monitoring applications in other industrial and healthcare environments, with new applications subject to validation against their specific requirements.
About AI Nose
AI Nose digitizes scent and chemical signals into machine-readable Smell ID data. Combining proprietary sensing hardware, edge AI, cloud-based fleet management, and a growing library of real-world chemical data, AI Nose enables machines to detect, distinguish, and learn from environmental signals that conventional vision and audio systems cannot capture. Ainos is developing AI Nose as a foundation for Chemical Intelligence across semiconductor manufacturing, robotics, industrial monitoring, healthcare, and other Physical AI applications.
About Ainos, Inc.
Ainos, Inc. ((NASDAQ:AIMD)(NASDAQ:AIMDW) is building Chemical Intelligence for Physical AI, giving machines a new way to understand the physical world by turning chemical signals in the air into digital information. Its AI Nose technology enables intelligent systems to sense and interpret changes in their surroundings, while Atmosphere Engine extends that intelligence toward environmental control. Together, they form a sensing-to-control architecture designed to help machines sense, understand, and ultimately optimize their environments across semiconductor manufacturing, robotics, industrial systems, healthcare environments, and other real-world applications where AI increasingly interacts with the physical world. Follow Ainos on X, formerly known as Twitter, @AinosInc, and LinkedIn to stay up to date. Visit Ainos' media room at https://ainos.suite.accessnewswire.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the uncertainty of the contemplated collaboration framework and the expected receipt of license fees, manufacturing license fees and other consideration thereunder; our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our licensed indications and product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Investor Relations
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How large is Ainos' new ASE purchase agreement?
The agreement is worth $9 million and covers 5,000 additional AI Nose systems. It is Ainos' largest single purchase order by value and follows completed delivery of 1,400 systems under the companies' previous $2.1 million agreement.
When will ASE pay Ainos for the additional AI Nose systems?
ASE will pay a 50% deposit of $4.5 million within 60 days of signing. The remaining 50% is payable through a payment request submitted after delivery and supported by delivery documentation. Revenue will be recognized as contractual performance obligations are satisfied.